Doctors 2.0 & You to address the "explosion of digital health tools" with new subjects, speakers, partners

5 - 6 June 2014, Paris, France.
Doctors 2.0 & You, partner of Stanford Medicine X and known for its 360° inclusive perspective on the patient, the physician, and digital tools, today announced 4th edition highlights. Remarking that "healthcare is now a recognized part of the explosion in social media, apps, quantified self and wearables," founder Denise Silber, confirms that "the June, 2014 program will provide an intensive look at the many moving parts of digital health and their results to date. How do patients and physicians benefit?"

Doctors 2.0 & You will bring attendees the latest insights and research on the ePatient and the digital doctor, individually and in communities, social media campaigns, eReputation, mobile apps, Serious Games and simulation, Quantified self and wearables including Google Glass and sensors. These tools will be envisaged from the standpoint of patients and physicians and other key stakeholders: pharma and device industries and suppliers, technology companies, payers, government. Participants originate from around the world and provide both a global and national perspective.

"So many people keep talking about digital, 2.0, social media... applied to the healthcare world. Doctors 2.0 & You helps make it happen, by spotting trends and talent and bringing la crème de la crème together. Doctors 2.0 & You is a best practice in Europe,” said Bernard Peyrical, Sanofi.

Some highlights from the 20 hours of activities including 22 parallel sessions and plenary, and 6 hours of Networking

  • Connected Objects, Quantified Self: Special activities around connected objects and quantified self will be developed for attendees thanks to the new Platinum Partnership with iHealthLabs Europe, founded by Uwe Diegel. Other quantified self players, ePatient and physician users, and pharma (Novartis) will provide their testimonials.
  • Google Glass: Four international pioneer Google Glass explorers will present exciting perspectives on health and medicine. Diversifying digital pharma
  • Pharma partners from hospitals and patient and physician communities will discuss relationships and results.
  • Dr Berci Mesko, founder of Webicina and medical futurist, will provide a limited seat Master Class on quality of web resources.
  • Award winning mobile apps and social media campaigns from Europe and the US will explain how they did it.
  • Three authors from the US, Hungary, and France will sign their books at the June 5th networking reception.
  • Stanford Medicine X and Doctors 2.0 & You will sponsor a medical student leader participant.
  • Announcement of the Doctors 2.0 & You Start Up Finalist who will fly to Palo Alto in September to present
  • Returning partners Novartis, Sanofi, LexisNexis and DocCheck will provide exciting activities in the exhibit hall.
  • Doctors 2.0 & You welcomes new supporting partners Ben's Friends and SOPE (Society of Physician Entrepreneurs).

For further information, please visit:
http://www.doctors20.com

About Doctors 2.0 & You
The Doctors 2.0TM & You conference series, organized by Basil Strategies, digital health consultancy (Paris), is the only international congress devoted to the understanding of how physicians use New Technologies, Web 2.0 tools and Social Media to communicate with colleagues, patients, payers, pharmaceutical companies and public agencies. The 4th edition will take place in Paris on June 5-6, 2014. The conference website and blog includes videos, past presentations, interviews, and other content.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...